论文部分内容阅读
应用 ＬＳＡＢ法对 ７６例乳腺癌伴淋巴结转移和无转移组 ＣＤ_(４４)、ＰＣＮＡ（增殖细胞核抗原）表达进行了免疫组化检测，并结合临床资料分析。结果显示：ＣＤ_(４４)阳性率在乳腺癌伴淋巴结转移组为 ７０． ６％，无转移组为 ４５． ２％，两组间差异显著（ Ｐ＜ ０． ０５），随着组织学分级的增高ＣＤ_(４４)。表达呈递增趋势，Ｉ级与Ⅱ、Ⅲ级间阳性率存在显著性差异（Ｐ＜０．０５）；ＰＣＮＡ阳性率在淋巴结转移组与无转移组间比较无显著差异，而与组织学分级间差异显著（Ｐ＜ ０． ０１）。 ＣＤ_(４４)与 ＰＣＮＡ表达存在平行关系。提示 ＣＤ_(４４)表达与乳腺癌淋巴结转移及预后有关，ＣＤ_(４４)、ＰＣＮＡ联合检测对评估乳腺癌患者预后有重要意义。
LSAB method was used to detect the expression of CD_(44) and PCNA (proliferating cell nuclear antigen) in 76 breast cancer patients with lymph node metastasis and non-metastasis group, and combined with clinical data analysis. The results showed that the positive rate of CD_(44) was 70.0% in breast cancer patients with lymph node metastasis. 6%, no metastasis group was 45. At 2%, there was a significant difference between the two groups (P < 0. 05), with an increase in histological grade CD_ (44). The expression showed an increasing trend, and there was a significant difference between the positive rate of grade I and grade II and grade III (P<0.05). The positive rate of PCNA was not significantly different between lymph node metastasis group and non-metastasis group, but it was correlated with histological grade. The difference was significant (P < 0. 01). There is a parallel relationship between CD_(44) and PCNA expression. It is suggested that the expression of CD_(44) is related to lymph node metastasis and prognosis of breast cancer. The combined detection of CD_(44) and PCNA has important significance in evaluating the prognosis of breast cancer patients.